Liraglutide is under development for the treatment of obesity, ileal pouch-anal anastomosis and Alzheimer's disease. It was also under development for non-alcoholic steatohepatitis, psoriatic ...

Liraglutide is under development for the treatment of obesity, ileal pouch-anal anastomosis and Alzheimer's disease. It was also under development for non-alcoholic steatohepatitis, psoriatic ...

Researchers in 2024 made unique and important discoveries that promise to help individuals suffering from addiction and their ...

StudyFinds' Dr. Faith Colemans explains why shopping for weight loss drugs online may save you money but endanger your health ...

The year had a lot to offer, from advanced therapies aimed at Lp(a), GLP-1, and other targets, to support for simpler ...

Tv Therapeutics Inc. (NASDAQ:VTVT – Get Free Report) was the target of a significant decline in short interest in the month ...

The following is a summary of “Association of Perioperative Glucagon-like Peptide-1 Receptor Agonist Use and Postoperative ...

Insurers said one major driver of higher premiums is the growing popularity of a relatively new class of injectable drugs to ...

Every January, millions of people start the new year vowing to lose weight. But in 2025, many of those hoping to shed the ...

The US Food and Drug Administration has approved the first generic referencing Victoza (liraglutide; Hikma Pharmaceuticals), ...

RTW Biotech added that last Monday, Corxel said it acquired worldwide rights to an oral small molecule glucagon-like peptide-1 receptor agonist known as CX11 from Suzhou, China-based Vincentage Pharma ...